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Background: Creutzfeldt-Jakob disease (CJD) is very rare human prion disease. But, neurologists take a 
key role in diagnosis, surveillance and management of the cases because of its complexity and difficulty 
in diagnosis of the disease. The aim of this study is to investigate the level of awareness and prepared-
ness of Korean neurologists on this rare disease. Methods: Survey sheets of self-administered question-
naire were given to Korean neurologists who participated in the 31st Annual Meeting of the Koran Neuro-
logical Association. Data from 133 respondents were conducted by descriptive analysis. Results: Their 
answers were as follows: About 62% of neurologists have experienced patients of CJD. Forty-four per-
cent of the patients were confirmed by brain biopsy. Most of neurologists (44%) were not confident to di-
agnose CJD and the reason why they felt hard to diagnose was due to the variable initial clinical mani-
festations (45.1%) and the lack of clinical experience (51.9%). Heidenheim variant CJD, proteinase sen-
sitive prionopathy, molecular subtypes of sporadic CJD, diagnostic criteria was not familiar term to Kore-
an neurologists (76.7%, 53.4%, 58.6%, and 62.4% respectively). Opinion for the most useful diagnostic 
tool was brain MRI (45.1%), CSF 14-3-3 protein (30.1%), typical EEG finding (36.8%) and gene (PRNP) 
test (42.9%). And they consider none of them are specific for the diagnosis of CJD (89.5%, 73.7%, 83.5%, 
91.7%, respectively). Most of the neurologist in this survey answered that the opportunity for education of 
CJD should be increased (67.7%). Conclusions: Most of neurologists have encountered CJD patients al-
though it is very rare disease. Some of the important and fundamental concepts of CJD were not correct-
ly recognized to Korean neurologists, necessitating a persistent support for updating knowledge and in-
formation.
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INTRODUCTION
Creutzfeldt-Jakob disease (CJD) is the most frequent hu-
man prion disease, although it is rare. The vast majority of 
CJD cases are sporadic (about 85%) and calculated preva-
lence of it is approximately 1-1.5 cases per one million popu-
lation a year with a worldwide distribution [1]. In Korea, the 
social anxiety increased a lot regarding import of beef from 
U.S. in 2008. As a result, CJD including variant CJD has be-
come the center of public interest in Korea. It requires profes-
sional experience in the course of diagnosis, and neurologist 
plays a critical role in the disease surveillance as well as in the 
diagnosis and management of it. The registration rate and ac-
curacy of diagnosis in Korea are still very low compared to 
that of developed countries. This study was aimed to investi-
gate the level of awareness, clinical experience and prepared-
ness of Korean neurologists who would encounter the patient 
of CJD at first place. This study would be used as basic data 
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for improving Korean surveillance system and also for better 
caring and educational system.
METHODS
The survey was performed for the participants on the 31st 
Annual Meeting of the Koran Neurological Association in 
April 2012. Total participants of the meeting were 688 (442 
specialists, 246 residents) and 133 neurologists voluntarily re-
sponded survey among them. A survey was considered to be 
the most efficient and accurate measure to evaluate neurolo-
gists’ current knowledge and practice regarding CJD. The 
survey questions were developed with 29-item questionnaire 
(appendix) covered 5 categories which were demographics of 
neurologists, clinical experience on CJD, diagnosis, terminol-
ogy and educational/reporting system. It was self-adminis-
trated survey and after reviewing of collected data, descrip-
tive statistics, such as percentages and sample size were used 
to describe how neurologists responded to specific questions. 
Most of the data are analyzed according to specialty of neu-
rology (resident or specialist of neurology).
RESULTS
Demographics of the participating neurologists on this 
survey
Among the neurologists who participated on the 31st An-
nual Meeting of the Koran Neurological Association in April 
2012, 133 members replied on our survey. Eighty-three mem-
bers were specialists of neurology and 51 members were resi-
dents of neurology. Age range of participants distributed from 
20s to 50s. About 75% of respondents worked for university 
hospital. The most frequent city they worked in was Seoul 
(53.4%) and Gyeonggi-do held the second rank (17.3%) (Ta-
ble 1).
Clinical experience on CJD
On this survey, 62.4% of the neurologists had cared CJD 
suspected patients directly and 15% had observed diagnosed 
cases in their hospital although they had not cared in person, 
and 19.5 % had not cared CJD suspected patients before (Fig. 
Table 1.Demographicsofneurologists(N=133)
N (%)
Age
20s 20 15.0
30s 87 65.4
40s 21 15.8
50s 5 3.8
Specialty of Neurology
Specialists 83 61.7
Residents 51 38.3
4th grade 24 18.0
3rd grade 16 12.0
2nd grade 10 7.5
Types of hospitals
University hospital 101 75.9
General hospital 7 5.3
Secondary hospital 6 4.5
Army medical officer/Public health doctor 7 5.3
Others 1 0.8
No response 11 8.3
The hospital location
    City Seoul 71 53.4
Busan 8 6.0
Daegu 4 3.0
Incheon 5 3.8
Gwangju 1 0.8
Daejeon 3 2.3
Ulsan 2 1.5
    Province Gyenggi-do 23 17.3
Gyeongsangnam-do 2 1.5
Gyeongsangbuk-do 2 1.5
Jeollanam-do 3 2.3
Jeollabuk-do 3 2.3
Chungcheongnam-do 4 3.0
Chungcheongbuk-do 1 0.8
Jeju-do 1 0.8
Total 133   100.0
Noresponse
3%(n=4)
Noexperience
20%(n=26)
Indirectly
15%(n=20) Directly
62%(n=83)
Fig. 1.PersonalexperienceofCJDpatients.
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Clinical
diagnosis
48%(n=57)
Uncertain
8%(n=10) Biopsyor
autopsy
proven
44%(n=52)
Total (n=119)
Fig. 2.Thetypesofdiagnosis.
Table 2.AwarenessofnationalstatusofpriondiseasesinKorea
How many CJD patients would occur in a year? How many CJD patients would be diagnosed in a year?
Resident (%) Specialist (%) Total (%) Resident (%) Specialist (%) Total (%)
<10 4 (7.8) 10 (12.2) 14 (10.5) 12 (23.5) 25 (30.5) 37 (27.8)
10-19 15 (29.4) 18 (22.0) 33 (24.8) 12 (23.5) 21 (25.6) 33 (24.8)
20-29 8 (15.7) 12 (14.6) 20 (15.0) 8 (15.7) 12 (14.6) 20 (15.0)
30-39 5 (9.8) 10 (12.2) 15 (11.3) 2 (3.9) 6 (7.3) 8 (6.0)
≥40 11 (21.6) 25 (30.5) 36 (27.1) 9 (17.6) 13 (15.9) 22 (16.5)
I don’t know 8 (15.7) 5 (6.1) 13 (9.8) 7 (13.7) 5 (6.1) 12 (9.0)
No response 0 (0) 2 (2.4) 2 (1.5) 1 (2.0) 0 (0) 1 (0.8)
Total 51 (100) 82 (100) 133 (100.0) 51 (100) 82 (100) 133 (100.0)
1). The percentage of the neurologists who made clinical di-
agnosis of CJD were 48% (n=57) and who made confirma-
tory diagnosis by brain biopsy or autopsy were 44% (n=52) 
(Fig. 2). Among respondents, 27.1% of them said that CJD 
might occur more than 40 cases a year and 24.8% said that 10 
to 19 cases might occur in Korea. Among 27.8% of neurolo-
gists answered that clinically diagnosed CJD might be less 
than 10 cases per year and 24.8% replied 10 to 19 cases a year 
and just 16.5% considered more than 40 cases a year in Korea 
(Table 2). 
Diagnosis
Whereas 48% of neurologists were confident in the diag-
nosis of CJD clinically unless it was atypical case, 44% were 
not confident. The Lack of clinical experience and limited in-
formation were the most difficult problems regarding the di-
agnosis of CJD (51.9%) and various clinical presentations in 
the early stage of disease were also playing a role as an obsta-
cle for correct diagnosis (45.1%). Respondents thought that 
most important diagnostic clues for suspecting CJD were 
rapid progressive cognitive decline (86.5%) and myoclonus 
(10.5%). Regarding useful diagnostic tools in order of impor-
tance were suggested that clinical findings (66.2%), brain MRI 
(45.1%), CSF 14-3-3 protein (30.1%), EEG (36.8%) and gene 
(PRNP) test (42.9%) in order. When positive finding of CSF 
14-3-3 protein is combined with rapidly progressive demen-
tia, 31.6% of respondents answered that the possibility of CJD 
is about 60 to 79% and 28.6% answered as 40 to 59%. If my-
oclonus is added to them, 40.8% of neurologists regarded the 
possibility of CJD is increased as high as 80 to 100% and 28.6% 
regarded as 60 to 79%. They responded that CSF 14-3-3 pro-
tein could be negative in 63.2% and 22.6% of them thought 
that initially it could be negative but it would be converted 
into positive in the course of disease. About 31% of neurolo-
gists estimated positive predictive values of CSF 14-3-3 pro-
tein in Korea might be 40 to 59%, 19.5% of them as 60 to 
79% and 17.3% of them as 20 to 39% respectively. With re-
gard to the question about the specificity of diagnostic tools, 
positive findings of clinical signs, specific brain MRI findings, 
CSF 14-3-3 protein and EEG periodic sharp wave complex 
were thought to be found in other diseases also (89.5%, 73.7%, 
83.5%, 91.7% respectively). About 50% of neurologists an-
swered that brain biopsy or autopsy was necessary just in case 
of confusion in the diagnosis of CJD whereas 45.1% replied 
that it was necessary although it was certain as CJD clinically. 
Similarly to this, 52.6% of respondents said they would trans-
fer just in case of confusion in the diagnosis of CJD for brain 
biopsy and 46.6% answered that they would definitely per-
suade caregiver for brain biopsy. Regarding transferring CJD 
suspected patients to superior hospitals for definite diagnosis 
or second opinion, 35.3% said they had transferred most of 
the patients for second opinion, 32.3% said that they hadn’t 
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Table 3.Self-evaluationofcapacityofdiagnosisandmanagementforpriondiseases
Questions related to diagnosis Response
All survey (n=133)
Resident (%) Specialist (%) Total (%)
Q1. Are you confident in the diagnosis of CJD? 1) Yes
2) Yes unless it is specific case
3) No.
0 (0)
19 (37.3)
32 (62.7) 
11 (13.4)
45 (54.9)
23 (31.7)
11 (8)
64 (48)
58 (44)
Q2. What do you think most difficult problem in the diagnosis of  
       CJD?
1) Various clinical presentation in the early stage
2) Lack of clinical experience & limited information 
3) Others
21 (41.2)
30 (58.8)
0 (0)
39 (47.6)
39 (47.6)
4 (4.9)
60 (45.1)
69 (51.9)
4 (3.0)
Q3. What do you think the most important clinical sign is in the  
       diagnosis of CJD patient?
1) Myoclonus 
2) Rapid progressive cognitive decline 
3) Visual symptom 
4) Cerebellar symptom 
5) Others
8 (15.7)
42 (82.4)
0 (0)
1 (2.0)
0 (0)
6 (7.3)
73 (89.0)
0 (0)
1 (1.2)
2 (2.4)
14 (10.5)
115 (86.5)
0 (0)
2 (1.5)
2 (1.5)
Q4. Please select most useful diagnostic tools among items  
       suggested as examples
1) Clinical findings 
2) Brain MRI ( including diffusion weighted image), 
3) CSF 14-3-3 protein 
4) EEG 
5) Gene test (PRNP mutation or codon 129 type)
34 (66.7)
4 (7.8)
9 (17.6)
0 (0)
2 (3.9)
54 (65.9)
9 (11.0)
6 (7.3)
1 (1.2)
12 (14.6)
88 (66.2)
13 (9.8)
15 (11.3)
1 (0.8)
14 (10.5)
Q7. What do you think about CSF 14-3-3 protein in CSF regarding  
       CJD?
1) It is always positive in CJD patients
2) It can be negative in CJD patients although it is rare
3) Initially it could be negative → positive later
4) I don’t know
5) No response
3 (5.9)
37 (72.5)
8 (15.7)
3 (5.9)
0 (0)
7 (8.5)
47 (57.3)
22 (26.8)
5 (6.1)
1 (1.2)
10 (7.5)
84 (63.2)
30 (22.6)
8 (6.0)
1 (0.8)
Q8. How many patients would be diagnosed as CJD among the  
       patients who revealed positivity in CSF 14-3-3 protein of CSF  
       in Korea?
1) <20%
2) 20-39% 
3) 40-59% 
4) 60-79% 
5) 80-100% 
6) I don’t know
7) No response
4 (7.8)
9 (17.6)
19 (37.3)
10 (19.6)
0 (0)
9 (17.6)
0 (0)
11 (13.4)
14 (17.1)
22 (26.8)
16 (19.5)
5 (6.1)
13 (15.9)
1 (1.2)
15 (11.3)
23 (17.3)
41 (30.8)
26 (19.5)
5 (3.8)
22 (16.5)
1 (0.8)
Q10. Do you think brain biopsy or autopsy is necessary for  
          definite diagnosis of CJD suspected patient?
1) It is necessary although it is certain clinically.
2) It is necessary just in case of diagnostic confusion 
3) It is not necessary
25 (49.0)
25 (49.0)
1 (2.0)
35 (42.7)
44 (53.7)
3 (3.7)
60 (45.1)
69 (51.9)
4 (3.0)
Q11. Would you transfer your CJD suspected patient for brain  
          biopsy if there is a specialized hospital for brain biopsy in  
          Korea?
1) Persuade caregiver for brain biopsy or autopsy
2) Transfer just in case of diagnostic confusion 
3) It is not necessary
22 (43.1)
29 (56.9)
0 (0)
40 (48.8)
41 (50.0)
1 (1.2)
62 (46.6)
70 (52.6)
1 (0.8)
Q12. Have you ever transferred your CJD suspected patient(s) to  
          superior hospital for seeking definite diagnosis or second  
          opinion?
1) transferred most of the patients for second opinion
2) transferred just in case of diagnostic confusion
3) haven’t transferred unless caregiver wanted to 
4) No response
15 (29.4)
15 (29.4)
21 (41.2)
0 (0)
32 (39.0)
26 (31.7)
22 (26.8)
2 (2.4)
47 (35.3)
41 (30.8)
43 (32.3)
2 (1.5)
Q5. What do you think about the possibility of CJD when patient  
        show rapidly progressive dementia, myoclonus and positive  
        4-3-3 protein in CSF?
1) <20% 
2) 20-39% 
3) 40-59% 
4) 60-79% 
5) 80-100% 
6) I don’t know
2 (3.9)
4 (7.8)
12 (23.5)
17 (33.3)
15 (29.4)
1 (2.0)
1 (1.2)
2 (2.4)
13 (15.9)
21 (25.6)
39 (47.6)
6 (7.3)
3 (2.3)
6 (4.5)
25 (18.8)
38 (28.6)
54 (40.6)
7 (5.3)
Q6. What do you think about the possibility of CJD when patient  
        show rapidly progressive dementia and positive 4-3-3 protein 
        in CSF?
2 (3.9)
11 (21.6)
15 (29.4)
17 (33.3)
4 (7.8)
2 (3.9)
2 (2.4)
15 (18.3)
23 (28.0)
25 (30.5)
9 (11.0)
7 (8.5)
4 (3.0)
26 (19.5)
38 (28.6)
42 (31.6)
13 (9.8)
9 (6.8)
Q9. What is your opinion about the specificity of diagnostic tools? 
       1. Rapidly progressive dementia 
       2. MRI finding 
       3. CSF 14-3-3(+)
       4. EEG finding (PSWC)
1) Only in CJD
2) Other diseases
3) I don’t know
4) No response
1 (2.0)
50 (98.0)
0 (0)
0 (0)
11 (21.6)
39 (76.5)
1 (2.0)
0 (0)
7 (13.7)
42 (82.4)
2 (3.9)
(0)
4 (7.8)
46 (90.2)
1 (2.0)
0 (0)
12 (14.6)
69 (84.1)
1 (1.2)
0 (0)
20 (24.4)
59 (72.0)
2 (2.4)
1 (1.2)
8 (9.8)
69 (84.1)
3 (3.7)
2 (2.4)
4 (4.9)
76 (92.7)
1 (1.2)
1 (1.2)
13 (9.8)
119 (89.5)
1 (0.8)
0 (0)
31 (23.3)
98 (73.7)
3 (2.3)
1 (0.8)
15 (11.1)
111 (83.5)
5 (3.8)
2 (1.5)
31 (23.3)
98 (73.7)
3 (2.3)
2 (1.5)
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transferred unless caregiver wanted to and 30.8% replied just 
in case of confusion in the diagnosis (Table 3).
Terminology and awareness
About the terminologies related to CJD, most of the respon-
dents answered that they know well or know a little at least 
about sporadic CJD (sCJD), variant CJD (vCJD), iatrogenic 
CJD (iCJD) and familiar CJD (fCJD) (49.6%, 41.4%, 43.6%, 
39.8% respectively). Regarding diagnostic criteria of sCJD by 
National CJD surveillance, Heidenheim variant CJD, 6 mo-
lecular subtypes of sCJD, PSPr (proteinase sensitive prionop-
athy)/VPSP (variably PSPr), and Heidenheim variant CJD, 
small proportion of them answered that they know well or 
know a little at least about those disease entities or criteria 
(37.6%, 41.4%, 45.9%, 21.8% respectively) (Fig. 3). Many re-
spondents replied that sCJD, iCJD and fCJD actually had oc-
curred in Korea before (94.7%, 75.2%, 44.4% respectively). 
However, only 49.6% thought that vCJD had not occurred 
and most of neurologists said they didn’t know whether PSPr, 
GSS, FFI, or sFI occurred or not in Korea (50.4%, 60.2%, 50.4%, 
63.2% respectively) (Fig. 4). 
About 8.5% of neurologists haven’t used terms “human mad 
cow disease” to explain sCJD but 18.8% had used it. The 60.9% 
of respondents said that term should not be used but 36.8% 
replied that it was not proper but it could be used to explain 
sCJD. Most of the neurologists (66.2%) had been asked about 
medical issues related to CJD and they are general public 
(33.1%), paramedics (21%) and doctors of other specialty 
(20%) (Table 4).
Knowwell Knowalittle Don’tknow
SporadicCJD
VariantCJD
IatrogenicCJD
FamilialCJD
WHOsCJDcriteria
NationalCJDsurveillanceunitcriteria
6subtypesofsCJD
PRNPgene
PSPr/VPSP
HeidenheimvariantCJD
0 20 40 60 80 100 120
66(49.6%)
63(47.4%)
4(3.0%)
55(41.4%)
64(48.1%)
13(9.8%)
58(43.6%)
69(51.9%)
6(4.5%)
53(39.8%)
61(45.9%)
19(14.3%)
19(14.3%)
63(47.4%)
51(38.3%)
9(6.8%)
9(6.8%)
41(30.8%)
83(62.4%)
46(34.6%)
78(58.6%)
23(17.3%)
51(38.3%)
59(44.4%)
15(11.3%)
46(34.6%)
71(53.4%)
10(7.5%)
19(14.3%)
102(76.7%)
Fig. 3.FamiliaritywithterminologyrelatedtoCJD.
Yes No Don’tknow
sCJD
vCJD
iCJD
fCJD
PSPr
GSS
FFI
sFI
0 50 100 150
122(91.7%)
3(2.3%)
8(6.0%)
40(30.1%)
66(49.6%)
27(20.3%)
100(75.2%)
11(8.3%)
21(15.8%)
59(44.4%)
26(19.5%)
47(35.3%)
25(18.8%)
15(11.3%) 67(50.4%)
23(17.3%)
28(21.1%) 80(60.2%)
44(33.1%)
21(15.8%)
67(50.4%)
19(14.3%)
28(21.1%)
84(63.2%)
Fig. 4.AwarenessofoccurrenceofeachdiseaseinKorea.
Table 4.Terminologyandawareness
Questions Response
All survey (n=133)
Resident (%) Specialist (%) Total (%)
Q3. Have you ever used the used the term “Human mad cow disease”  
        when you explain sporadic CJD?
1) Yes I have frequently
2) Yes I have a few times
3) No. I haven’t.
1 (2.0)
9 (17.6)
41 (80.4)
0 (0)
16 (19.5)
66 (80.5)
1 (0.8)
25 (18.8)
107 (80.5)
Q4. Do you think the term “Human mad cow disease” is proper for  
        explaining sporadic CJD?
1) Yes. It is proper
2) No. But it can be used.
3) No. It should not be used.
4) No response
1 (2.0)
20 (39.2)
29 (56.9)
1 (2)
0 (0)
29 (35.4)
52 (63.4)
1 (1.2)
1 (0.8)
49 (36.8)
81 (60.9)
2 (1.5)
Q5. Have you ever been asked about the medical questions regarding CJD  
        from others?
1) No.
2) Yes.
26 (51.0)
25 (49.0)
19 (23.2)
63 (76.8)
45 (33.8)
88 (66.2)
Q6. Who asked you? 1) Other neurologists.
2) Doctors of other specialty.
3) Paramedics
4) General public
5) Never asked
1 (2.0)
5 (9.8)
2 (3.9)
17 (33.3)
26 (51.0)
2 (2.4)
15 (18.3)
19 (23.3)
27 (32.9)
19 (23.2)
3 (2.3)
20 (15.0)
21 (15.8)
44 (33.1)
45 (33.8)
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Educational/reporting system
About 44% of neurologists on this survey had heard of the 
reporting system of suspected CJD patient to public health 
center but don’t know well about it, 34.1% are well aware of it 
and 11.3% said that they never heard of it. Most of the re-
spondents had participated in the lecture or educational pro-
grams related to CJD 1 to 2 times (52.6%) and 24.1% partici-
pated more than 3 times but 21.8% never had chance to par-
ticipated in them. About the question asking the necessity of 
increasing educational opportunity for neurologists, 67.7% of 
respondents said “yes” but 30.8% of them thought it wss still 
enough. About 72.9% of respondent replied that they would 
participate in the educational program as far as circumstances 
permit and 23.3% said they would participate for sure. Re-
garding partial economical supporting system for medical ex-
penses of CJD patients as rare and incurable disease, 45.1% of 
respondents said that they had never heard of that and 37.6% 
had heard of it but don’t know well and the proportion of the 
respondents who knew about it was as low as 16.5% (Table 5). 
DISCUSSION
According to the reported incidence of CJD, it seems to be 
50 to 75 patients per year in Korea. Although the incidence is 
very low, it is important as a fatal disease without cure and 
should be considered as first differential diagnosis of patients 
with rapidly progressive dementia. In 2011, the first Korean 
case of iatrogenic CJD was reported which also increased the 
public interest among the people [2]. So, the possibility of 
transfection to other persons by medical devices, operational 
tools or transfusion also should be considered.
On this survey about 44% of neurologists (n=52) encoun-
tered CJD patients confirmed by biopsy or autopsy (Fig. 2) 
and it is very high percentage when we consider the low rate 
of biopsy or autopsy performance in Korea. The reason why 
it showed high proportion might be the overlapping patients 
with CJD among the respondents. Twenty-seven percent of 
respondents answered that CJD might occur more than 40 
cases a year but 52.6% of them considered clinically diagnosed 
CJD would be less than 20 cases, so most neurologists recog-
nized the number of real occurrence of CJD is larger than 
that of clinically diagnosed cases in Korea. Actually, accord-
ing to the reports of KCDC, about 30 cases of sporadic CJD 
have been reported since 2008 annually but estimated occur-
rence rate of CJD is more than 50 to 60 cases a year in Korea 
[3]. We do not know the real number of CJD cases because 
the definite diagnosis of CJD is very rare, and possible diag-
nosis seems not so valid in Korea. Large proportion of Kore-
Table 5.Educational/reportingsystem
Questions Response
All survey (n=133)
Resident (%) Specialist (%) Total (%)
Q1. Do you know the reporting system of suspected CJD patient  
        to public health center?
1) Yes 
2) I’ve heard but don’t know well
3) I’ve never heard of it
18 (35.3)
26 (51.0)
7 (13.7)
28 (34.1)
46 (56.1)
8 (9.8)
46 (34.6)
72 (54.1)
15 (11.3)
Q2. How many times have you participated in the lecture or  
       educational program related to CJD (or prionopathy)?
1) ≥3
2) 1-2
3) I’ve never participated in it.
5 (9.8)
24 (47.1)
22 (43.1)
27 (32.9)
46 (56.1)
7 (8.5)
2 (2.4)
32 (24.1)
70 (52.6)
29 (21.8)
2 (1.5)
Q3. Do you think educational opportunity for neurologists  
       regarding CJD (or prionopathy) should be increased?
1) Yes. 
2) It is still enough.
3) It is not necessary anymore
4) No response
40 (78.4)
11 (21.6)
0 (0)
50 (61.0)
30 (36.6)
1 (1.2)
1 (1.2)
90 (67.7)
41 (30.8)
1 (0.8)
1 (0.8)
Q4. Would you participate in the educational program for CJD  
       (or prionopathy) if it would be held in the future?
1) Yes.
2) Participate as far as circumstances permit.
3) No
4) No response
12 (23.5)
37 (72.5)
2 (3.9)
0 (0)
19 (23.2)
60 (73.2)
2 (2.4)
1 (1.2)
31 (23.3)
97 (72.9)
4 (3.0)
1 (0.8)
Q5. Have you ever heard of the partial supporting system for  
       medical expenses of CJD patients as rare and incurable  
       disease?
1) Yes 
2) I’ve heard but don’t know well
3) I’ve never heard of it
4) No response
8 (15.7)
21 (41.2)
22 (43.1)
0 (0)
14 (17.1)
29 (35.4)
38 (46.3)
1 (1.2)
22 (16.5)
50 (37.4)
60 (45.1)
1 (0.8)
Neurologists’ViewsonPrionDiseasesinKorea 15
http://dx.doi.org/10.12779/dnd.2013.12.1.9 www.dementia.or.kr
an neurologists regarded the incidence as lower than that of 
calculated incidence. About 62% of the neurologists on this 
survey had experience of caring CJD patients personally. 
When we added the number of respondents who just ob-
served CJD patient diagnosed in their hospital although they 
did not care personally, 77.4% of neurologists had experi-
enced CJD patient directly or indirectly. So, most of the Ko-
rean neurologists who participated in the survey had experi-
ence of CJD although it is very rare disease.
Rapidly progressive dementia and myoclonus would be the 
main clinical signs of sporadic CJD [4]. On this survey, 86.5% 
of respondents answered that rapidly progressive dementia 
would be the most important clinical sign and 10.5% of re-
spondents replied myoclonus would be. Question about the 
order of clinical usefulness as diagnostic tool was as follows - 
clinical signs, CSF 14-3-3 protein, brain MRI, gene test and 
EEG in order. Among them, brain MRI was not included in 
revised 1998 diagnostic criteria of World Health organization 
for sCJD but it is currently modified to incorporate MRI fea-
ture [5, 6]. Brain MRI showed higher sensitivity and specific-
ity (96% and 93% respectively) in diagnosis of CJD [7] over 
CSF 14-3-3 protein (sensitivity 86%, specificity 68%)[8] or 
EEG (sensitivity 64%, specificity 91%)[9]. Regarding ques-
tion asking diagnostic specificity of each tool on the basis of 
95% specificity, most of the neurologists answered that any 
positive finding of them would be found in other diseases 
too. So lack of definite diagnostic tool could be one of the 
causes of increasing difficulty in the diagnosis of CJD in clini-
cal setting. CSF 14-3-3 protein shows low specificity because 
it can reveal false positive results in other disease such as her-
pes simplex encephalitis, hypoxic brain damage, brain metas-
tasis, paraneoplastic syndrome or metabolic syndrome [10]. 
So other CSF markers such as tau protein or S100b protein 
are used combined with CSF 14-3-3 protein in some labora-
tories of other countries [11]. By using cell culture of neurons 
and glial cells, it is suggested that CSF 14-3-3 protein is just a 
marker of injured brain tissue rather than that of CJD [12]. 
The annual number of suspected CJD patients referred to 
KCDC is increasing constantly from 51 cases in 2008 to 91 
cases in 2010. The positive ratio of CSF 14-3-3 protein among 
referred cases is more than 50% [3]. About 50% of them who 
showed CSF 14-3-3 positivity are reported as CJD in Korea. 
Final diagnosis of other cases who showed CSF 14-3-3 pro-
tein positive are composed of infectious disease (43%), toxic-
metabolic disease (23%), epileptic disorder (10%), tumor 
(7%) and others (15%) (in submission) . This was in accor-
dance with the result of answers from neurologists who esti-
mated positive predictive value of CSF 14-3-3 protein was 
from 40 to 59%. When positive finding of CSF 14-3-3 protein 
is combined with rapidly progressive dementia, 31.6% of re-
spondents answered that the possibility of CJD would be 
about 60 to 79%. If myoclonus is added to them 40.8% of 
neurologists regarded the possibility of CJD would increase 
as high as 80 to 100%. So, rapid progressive dementia, myoc-
lonus and CSF 14-3-3 protein play major role in the diagnosis 
of CJD in Korean clinical setting. Many neurologists (44%) 
were not confident in the diagnosis of CJD and it was more 
evident in residents (62.7%) than specialists (31.7%). Two 
main problems of this diffidence might be due to the lack of 
clinical experiences because CJD is rare disease (51.9%) and 
it showed non-specific initial clinical findings (45.1%). So it 
suggested that there is in need of educational programs to re-
lieve these problems especially for residents. Many neurolo-
gists (35%) would transfer CJD suspected patient to other su-
perior hospital for further evaluation or second opinion. This 
result might be derived from the burden of confirmative di-
agnosis as CJD which is fatal disease without cure and from 
difficulties in differential diagnosis because of its variable ini-
tial clinical presentations. The most common first sign was 
reported as cognitive decline such as deficit in attention, me-
mory or judgment [13]. In addition to it, emotional and be-
havioral change, sleep disorder are also common. Myoclonus, 
which is especially induced by startling stimulus, might be 
observed 90% of cases in the course of disease progression. 
Extrapyramidal symptoms such as hypokinesia or cerebellar 
symptoms such as nystagmus, ataxia could be found in two 
thirds of the patients and 20 to 40% of cases showed them as 
main symptoms [13]. For example, it was reported that iatro-
genic CJD has a tendency of presenting cerebellar symptoms 
in the early stage of disease [14]. Pyramidal signs such as in-
creased deep tendon reflex or positive Babinski sign can be 
found in 40-80% of patients. After following up 52 cases of 
young sCJD patients aged less than 50 years old, it was re-
ported that psychiatric symptoms could be easily found as it 
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is observed in variant CJD [15]. And there are some subtypes 
or variant form of CJD regarding main focal neurologic signs. 
Heidenhain variant CJD which present visual symptoms at 
first and Oppenheimer-Brownell variant CJD which shows 
mainly cerebellar symptoms could be examples of them.
About 85 to 90% of neurologists on this survey replied that 
they know well or know a little at least about sCJD, iCJD, fCJD, 
and vCJD. On the other hand, regarding Heidenheim variant 
CJD, PSPr (Proteinase sensitive prionopathy)/VPSP (Variably 
PSPr), Gerstamn-Strausler-Scheinker syndrome (GSS), fatal 
familiar insomnia (FFI), sporadic fatal insomnia and 6 mo-
lecular subtypes of sCJD, large proportion of them answered 
that they did not know about those disease entity (76.7%, 
53.4%, 60.2%, 50.4%, 63.2%, 58.6% respectively). So, it re-
vealed the necessity of education afterward regarding those 
rare form of prion diseases. Regarding 6 molecular subtypes 
of sCJD, one of the possible reasons that it showed low recog-
nition rate among Korean neurologists might be due to low 
incidence of brain biopsy or autopsy performance because 
molecular subtype is decided by those studies. In Korea, case 
of vCJD has never been reported but it was in the center of 
great social issues across the nation related to import of beef 
from U.S. in 2008. However, 40 neurologists (30%) believed 
that vCJD had been reported in Korea and 27 neurologists 
(20.3%) answered that they didn’t know whether it was re-
ported or not. About half of them are specialist working in 
university hospital. Eleven neurologists answered that there 
had not been sCJD in Korea or they did not know whe ther it 
occurred or not, although 9 of them are residents of universi-
ty hospital in Seoul. Some of respondents (18.8%) have used 
the term “human mad cow disease” to explain sCJD and 36.8% 
of neurologists answered that this term could be usable al-
though they know it is not proper. These results show possi-
bilities of evoking social problems. In Korea, “human mad 
cow disease” means vCJD but it is not appropriate term and 
should be modified to other term “CJD related to mad cow 
disease”. The proportions of neurologists who answered that 
they knew the diagnostic criteria of sporadic CJD suggested 
by WHO or National CJD surveillance Unit was very low as 
19% and 9% respectively which showed low awareness of 
CJD diagnostic criteria. 
For definite diagnosis as CJD, it is required to confirm pro-
teinase K resistant protein in Western blotting and to identify 
abnormal prion protein in immunohistochemistry on brain 
tissue. Triad of pathologic finding of CJD are neuronal cell 
loss, gliosis and vacuolization in the brain and spinal cord 
[16]. In this survey, 51.9% of neurologists answered that they 
would recommend brain biopsy for definite diagnosis just in 
case of confusion in the clinical diagnosis of CJD. On the 
contrary to it, 45.1% of respondent said that brain biopsy is 
necessary even though it is clinically certain. The brain tissue 
is not easily obtainable in Korea so the total number of re-
ferred brain tissue for CJD is just less than 5 (2cases in 2011, 
5cases in 2010, 4cases in 2009, 2008, 2007) annually so, the 
number of actual brain biopsy is too small compared with 
the need of neurological specialists. Contradictory realization 
about brain biopsy or autopsy in Korea may contribute to the 
reluctant attitude to it. On top of it, surgeons also show reluc-
tance to perform brain biopsy because of the burden of inva-
sive procedure to this fatal transmissible disease. 
Although definite diagnosis of CJD requires examination 
on brain tissue according to diagnostic criteria, the burden of 
invasive procedure described above and the possibility of 
false negative finding when brain tissue with no invasion is 
acquired also must be considered. University of California, 
San Francisco (UCSF) proposed diagnostic criteria of CJD 
based on brain MRI in 2010 [7]. Owing to the usefulness of 
diffusion-weighed image (DWI), they didn’t recommend 
brain biopsy anymore in most cases of CJD patients and it is 
performed when it showed uncertain feature after DWI. In 
Korea, comparative analysis is required to evaluate which 
combination of diagnostic tools can be the most accurate and 
efficient method for diagnosis of CJD. 
In summary, most of the Korean neurologists have encoun-
tered CJD although it is very rare disease. They are well rec-
ognized about the annual occurrence of CJD, sensitivity and 
specificity of diagnostic tools which was nearly the same with 
that of reported in the literature. They had difficulty in the di-
agnosis of CJD because of the variable initial clinical presen-
tations in the early stage and the lack of clinical experience 
especially in residents. They also have some misunderstand-
ing not only in the subtypes of CJD or diagnostic criteria but 
also in the vCJD which was in the center of great public inter-
est in Korea. These suggested the necessity of educational 
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system for neurologists. The term “Human mad cow disease” 
should be reconsidered because of its potential possibilities 
that might evoke social problems. Although neurologists do 
not seem to be firmly prepared to CJD, 66.2% of them are 
asked about the CJD from many paramedics, doctors of oth-
er specialty or general public. Therefore considering the role 
of primary information providers of CJD, the educational op-
portunity for the neurologists seems very important to avoid 
the delivery of false information. About 67% of respondents 
also replied that they need more educational opportunity 
than now. Korean neurological association tried to raise the 
concern about CJD for neurologists through 2010 CJD sym-
posium and it contributed somewhat to increased number of 
CJD suspected patients who were referred to Korea Centers 
For Disease Control and Prevention (KCDC) afterward [5]. 
This might be the good example which enhanced the con-
cerns about CJD among the neurologists by educational sym-
posium. The essential knowledge about CJD in clinical set-
ting is not so much that regular small workshop for neuro-
logical resident or specialist would be adequate. Most of the 
neurologists are not aware of the reporting system of patients 
or supporting system for medical expenses, so the regular 
public relations also seem necessary for neurologists. 
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Appendix
I.Demographicsofneurologists
1. Where is your hospital?
□ Seoul □ Busan □ Daegu □ Incheon □ Gwangju □ Daejeon □ Ulsan □ Gyeonggi-do □ Gangwon-do □ Gyeongsangnam-do 
□ Gyeongsangbuk-do □ Jeollabuk-do □ Chungcheongnam-do □ Chungcheongbuk-do □ Jeju-do
2. Are you specialist or resident of department of neurology?
□ Specialist □ Resident
3. What kind of hospital are you working for?
□ University hospital □ General hospital □ Secondary hospital
□ Private hospital □ Army medical officer/Public health doctor □ Others___________
4. How old are you?
□ 20s □ 30s □ 40s □ 50s □ 60s □ 70s
II.ClinicalexperienceonCJD
1. Have you ever cared CJD suspected patients before?
1) I’ve directly cared → go to 2.
2) I’ve seen diagnosed case in our hospital although I haven’t directly cared → go to 3.
3) I’ve never cared CJD patients → go to 3.
2. Among the patients you’ve cared, how many patients were confirmed by the method described below?
1) By brain biopsy or autopsy (    ) cases
2) By clinical diagnosis (    ) cases
3) Clinically suspected case although it was not definite because of transferring to other hospital (    ) cases
3. How many patients of CJD would occur including non-diagnosed cases in Korea per year?
1)<10 2) 10-19 3) 20-29 4) 30-39 5) ≥40 6) I don’t know
4.  How many patients of CJD would be diagnosed in Korea per year?
1)<10 2) 10-19 3) 20-29 4) 30-39 5) ≥40 6) I don’t know
III.Diagnosis
1. Are you confident in the diagnosis of CJD?
1) Yes. I’m confident in any cases. 2) Yes unless it is specific case. 3)No.
2. What do you think most difficult problem in the diagnosis of CJD?
1) Various clinical presentation in the early stage
2) Lack of clinical experience and limited information as rare disease
3) Others : ________________________
3. What do you think the most important clinical sign or symptom is in the diagnosis of CJD patient?
1) myoclonus 2) rapid progressive cognitive decline 3) visual symptom 4) cerebellar symptom 5) others ____________________
4. Please select useful diagnostic tools in order of importance among items suggested as examples
 
1st:  ① ② ③ ④ ⑤ ⑥ 
2nd:  ① ② ③ ④ ⑤ ⑥ 
3rd:   ① ② ③ ④ ⑤ ⑥ 
4th:  ① ② ③ ④ ⑤ ⑥ 
5th:   ① ② ③ ④ ⑤ ⑥ 
6th:   ① ② ③ ④ ⑤ ⑥ 
< Examples>
① Clinical findings ② Brain MRI ( including diffusion weighted image) ③ CSF 14-3-3 protein ④ EEG 
⑤ Gene test (PRNP mutation or codon 129 type) ⑥ Others: ________________________
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5. What do you think about the possibility of CJD when patient show rapidly progressive dementia, myoclonus and positive 4-3-3 protein in CSF?
1) <20% 2) 20-39% 3) 40-59% 4) 60-79% 5) 80-100% 6) I don’t know
6. What do you think about the possibility of CJD when patient show rapidly progressive dementia and positive 4-3-3 protein in CSF?
1) <20% 2) 20-39% 3) 40-59% 4) 60-79% 5) 80-100% 6) I don’t know
7. What do you think about 14-3-3 protein in CSF regarding CJD?
1) It is always positive in CJD patients
2) It can be negative in CJD patients although it is rare
3) Initially it could be negative but it would be converted into positive in the course of disease eventually
4) I don’t know
8. How many patients would be diagnosed as CJD among the patients who revealed positivity in 14-3-3 protein of CSF in Korea?
1) <20% 2) 20-39% 3) 40-59% 4) 60-79% 5) 80-100% 6) I don’t know
9. What is your opinion about the specificity of diagnostic tools below?
10. Do you think brain biopsy or autopsy is necessary for definite diagnosis of CJD suspected patient?
1) It is necessary although it is certain clinically.
2) It is necessary just in case of confusion in the diagnosis of CJD
3) It is not necessary.
11. Would you transfer your CJD suspected patient for brain biopsy if there is a specialized hospital for brain biopsy in Korea?
1) I would definitely persuade caregiver for brain biopsy or autopsy
2) I would transfer just in case of confusion in the diagnosis of CJD
3) It is not necessary
12. Have you ever transferred your CJD suspected patient(s) to superior hospital for seeking definite diagnosis or second opinion?
1) I have transferred most of the patients for second opinion
2) I have transferred just in case of confusion in the diagnosis of CJD
3) I haven’t transferred unless caregiver wanted to remarkably
IV.Terminologyandawareness
1. Do you know the terms below?
Ddiagnostic tools It is found only in CJD (more than 95%) It can be found in other diseases I don’t know
Rapidly progressed dementia & myoclonus
Specific brain MRI finding (compatible with CJD)
CSF 14-3-3 protein positive
EEG periodic sharp wave complex
   (compatible with CJD)
Term Yes I know a little No
sCJD Sporadic Creutzfeldt-Jakob disease
iCJD Iatrogenic Creutzfeldt-Jakob disease
fCJD Familial Creutzfeldt-Jakob disease
vCJD Variant Creutzfeldt-Jakob disease
Heidenhein variant Creutzfeldt-Jakob disease
PSPr (Proteinase sensitive prionopathy)/VPSP (Variably PSPr) 
PRNP gene
6 subtypes of sCJD (MM1, VV1, MM2 cortical, MV2, VV2, MM2)
WHO diagnositic criteria of sCJD 
National CJD surveillance unit criteria of sCJD 
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2. Do you think the human prion disease below have ever occurred in Korea?
3. Have you ever used the term “Human mad cow disease” when you explained sporadic CJD?
1) Yes I have frequently
2) Yes I have a few times
3) No I haven’t
4. Do you think the term “Human mad cow disease” is proper for explaining sporadic CJD?
1) Yes It is proper
2) No but it can be used.
3) No. It should not be used.
5. Have you ever been asked about the medical questions regarding CJD from others?
1) No 2) Yes → go to 4.
6. Who asked you about CJD?
1) Other neurologist
2) Doctors of other specialty.
3) Paramedics
4) General public
V.Educational&Reportingsystem
1. CJD is legally designated infectious disease of group 3. Do you know the reporting system to public health center when suspected CJD patient occurs?
1) yes 2) I’ve heard but don’t know well. 3) I’ve never heard of it.
2. How many times have you participated in the lectures or educational programs related to CJD (or prionopathy)?
1) ≥3 2) 1-2 3) I’ve never participated in it.
3. Do you think educational opportunity for neurologists regarding CJD (or prionopathy) should be increased?
1) Yes 2) It is still enough. 3) It is not necessary any more
4. Would you participate in the educational program for CJD (or prionopathy) if it would be held in the future?
1) Yes 2) I would participate as far as circumstances permit 3) No.
5. Have you ever heard of the partial supporting system for medical expenses of CJD patients as rare and incurable disease?
1) Yes 2) I’ve heard but don’t know well. 3) I’ve never heard of it.
Term Yes No I don’t know
sCJD Sporadic Creutzfeldt-Jakob disease
iCJD Iatrogenic Creutzfeldt-Jakob disease
fCJD Familial Creutzfeldt-Jakob disease
vCJD Variant Creutzfeldt-Jakob disease
PSPr (Proteinase sensitive prionopathy)/VPSP (Variably PSPr) 
GSS Gerstmann-Straussler-Scheinker Disease
FFI Fatal familial insomnia
sFI Sporadic fatal insomnia
